Conference Paper: Telbivudine vs Lamivudine in HBeAg-Positive Patients with CHB: Two-Year Efficacy and Predictors of Response

File Download
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleTelbivudine vs Lamivudine in HBeAg-Positive Patients with CHB: Two-Year Efficacy and Predictors of Response
AuthorsLai, CL
Gane, E
Hsu, CW
Chen, YC
Thongsawat, S
Wang, Y
Chen, Y
Naoumov, N
Han, SH
Hwang, SG
Lim, SG
Brown, NA
Issue Date2007
DC Field
Value
dc.contributor.authorLai, CL
dc.contributor.authorGane, E
dc.contributor.authorHsu, CW
dc.contributor.authorChen, YC
dc.contributor.authorThongsawat, S
dc.contributor.authorWang, Y
dc.contributor.authorChen, Y
dc.contributor.authorNaoumov, N
dc.contributor.authorHan, SH
dc.contributor.authorHwang, SG
dc.contributor.authorLim, SG
dc.contributor.authorBrown, NA
dc.date.accessioned2010-09-25T20:51:17Z
dc.date.available2010-09-25T20:51:17Z
dc.date.issued2007
dc.identifier.hkuros133878
dc.identifier.urihttp://hdl.handle.net/10722/102946
dc.languageeng
dc.relation.ispartofOral Presetnation at the Parallel Oral Session of the HBV Day of the 17th Asian Pacific Association for the Study of the Liver (APASL) Conference on March 28
dc.titleTelbivudine vs Lamivudine in HBeAg-Positive Patients with CHB: Two-Year Efficacy and Predictors of Response
dc.typeConference_Paper